Market Cap
$4.1B
VKTX
Viking Therapeutics, Inc.
$29.94 ▼ -1.87%
Prev close $30.51Market cap$4.1B
ConsensusStrong Buy
12-mo target$94.82 (+216.7%)
▲ Bullish
Analyst conviction 9/10
Insider Selling Cluster (3 insiders)28 New Institutional Positions11 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on VKTX right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Analyst Consensus
Strong Buy (88%)
Inst. Holders
50 funds
Inst. Value
$2.6B
Inst. Activity
28 buys / 11 sells
Insider Activity
$149.9K buy / $6.3M sell
Insider Net $
-$6.1M
Social Sentiment
50° Neutral
SEC Reports
3
Price chart 30d -11.9%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 28, 2026 other
Aug 8, 2026 SEC Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior Notes
Gross Proceeds to Viking Approximately $575 Million SAN DIEGO, Sept. 28, 2026 /PRNewswire/ -- Viking
Three top executives at Viking Therapeutics (CEO, CFO, COO) collectively sold $6.27M in stock on the same day (July 29,
CLUSTER — Impact 4/10
Aug 1, 2026 Insider
Kelly-Gemmell Dorothy Elizabeth was granted 40,800 shares
Director
Aug 1, 2026 Insider
Jul 30, 2026 SEC Kelly-Gemmell Dorothy Elizabeth was granted 6,333 shares
Director
VKTX CFO and COO sold a combined $1.32M in open-market sales on July 29, 2026, at ~$33.47/share, following non-cash stoc
CLUSTER — Impact 3/10
Jul 29, 2026 Insider
Mancini Marianna sold 18,217 shares
Chief Operating Officer @ $33.47 ($609.6K)
Jun 30, 2026 Inst.
STATE STREET CORP — ADD
5,606,394 shares ($218.7M)
Jun 30, 2026 Inst.
AMERIPRISE FINANCIAL INC — ADD
2,156,083 shares ($84.1M)
Analyst ratings buy % -3.3%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
88% rate it Buy or better · 26 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 23, 2026 | Truist Securities | MAINTAIN | Buy | 55% |
| Aug 11, 2026 | JP Morgan | MAINTAIN | Overweight | 55% |
| Jul 30, 2026 | Canaccord Genuity | MAINTAIN | Buy | 47% |
| May 28, 2026 | Lake Street | INITIATE | Buy | 45% |
| May 1, 2026 | BTIG | REITERATE | Buy | 53% |
| Apr 30, 2026 | Cantor Fitzgerald | MAINTAIN | Overweight | 49% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 9 | 14 | 3 | 0 | 0 | 88% | |
| Aug 1, 2026 | 9 | 14 | 3 | 0 | 0 | 88% | |
| Jul 1, 2026 | 9 | 14 | 3 | 0 | 0 | 88% | |
| Jun 1, 2026 | 9 | 14 | 3 | 0 | 0 | 88% | |
| May 1, 2026 | 9 | 13 | 3 | 0 | 0 | 88% | |
| Apr 1, 2026 | 9 | 13 | 3 | 0 | 0 | 88% | |
| Mar 1, 2026 | 9 | 13 | 2 | 0 | 0 | 92% | |
| Feb 1, 2026 | 9 | 13 | 2 | 0 | 0 | 92% |
Price targets
Where 19 covering analysts think VKTX trades over the next 12 months.
$94.82 +216.7% upside Strong Buy
Current$29.94 Low$38.00 Median$95.00 High$125.00 19 analysts
$38.00$125.00
Analyst rating Strong Buy· 1.4/5 as of Oct 2, 2026
Social media sentiment mood +13.6%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
50°
Neutral
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
3 SEC filing reports analyzed · 0 bullish, 0 bearish, 0 mixed, 3 neutral · avg impact 3.0/10.
NEUTRALCLUSTER4/10
Three top executives at Viking Therapeutics (CEO, CFO, COO) collectively sold $6.27M in stock on the
Aug 8, 2026
NEUTRALCLUSTER3/10
VKTX CFO and COO sold a combined $1.32M in open-market sales on July 29, 2026, at ~$33.47/share, fol
Jul 30, 2026
NEUTRALDEFA14A2/10
Viking Therapeutics is holding its 2026 annual shareholder meeting to vote on director elections, au
Apr 1, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 28, 2026
other
Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior Notes
Gross Proceeds to Viking Approximately $575 Million SAN DIEGO, Sept. 28, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Nasdaq: VKTX), a clinical-sta
Sep 28, 2026
other
Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm
NEW YORK, Sept. 28, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors o
Sep 24, 2026
other
Viking Therapeutics Prices Upsized $500 Million Offering of Common Stock and Convertible Senior Notes
SAN DIEGO, Sept. 24, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the developm
Sep 24, 2026
short_volume
Short Volume: VKTX — 68.3% short (9.5M / 13.9M)
Short: 9,520,691 | Exempt: 925,965 | TRF Vol: 13,940,596 | Short Ratio: 68.3% | Off-exchange volume (dark pool + OTC)
Sep 23, 2026
other
Viking Therapeutics Announces Proposed Offerings of Common Stock and Convertible Senior Notes
SAN DIEGO, Sept. 23, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the developm
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-1.07 | $-1.38–$-0.66 | -31.5% | +0.0% | 9↑ 6↓ | $0.0B | 16 |
| Next Q | $-1.10 | $-1.48–$-0.67 | 20.1% | +0.0% | 7↑ 9↓ | $0.0B | 16 |
| Current FY | $-4.61 | $-5.35–$-3.81 | -44.4% | +0.0% | 9↑ 7↓ | $0.0B | 16 |
| Next FY | $-4.40 | $-6.04–$-2.23 | 4.4% | -1.9% | 11↑ 5↓ | $0.0B | 16 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-1.065 | — |
| 7d ago | $-1.065 | — |
| 30d ago | $-1.065 | — |
| 60d ago | $-1.100 | +0.035 |
| 90d ago | $-1.100 | +0.035 |
Institutional ownership
Which big funds own VKTX (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $2.6B total value (67,858,931 shares) as of 2026-Q2. Top holders: NOMURA, FMR, BlackRock,. Net buying activity: 28 institutions added/increased vs 11 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| NOMURA ASSET MANAGEMENT CO LTD | 0 | $0.00 | 0.0% | — |
| FMR LLC | 6,335,756 | $247.2M | 9.3% | — |
| BlackRock, Inc. | 6,189,649 | $241.5M | 9.1% | — |
| STATE STREET CORP | 5,606,394 | $218.7M | 8.3% | ADD +27.5% |
| VANGUARD CAPITAL MANAGEMENT LLC | 5,053,663 | $197.1M | 7.4% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4,484,263 | $174.9M | 6.6% | — |
| TWO SIGMA INVESTMENTS, LP | 3,937,414 | $153.6M | 5.8% | — |
| MORGAN STANLEY | 3,486,040 | $136.0M | 5.1% | — |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 2,906,500 | $113.4M | 4.3% | — |
| AMERIPRISE FINANCIAL INC | 2,156,083 | $84.1M | 3.2% | ADD +28.4% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| STATE STREET CORP | ADD | 4,395,557 | 5,606,394 | +27.5% | $218.7M |
| AMERIPRISE FINANCIAL INC | ADD | 1,678,745 | 2,156,083 | +28.4% | $84.1M |
| BNP PARIBAS FINANCIAL MARKETS | ADD | 540,499 | 981,700 | +81.6% | $38.3M |
| UBS Group AG | TRIM | 1,347,472 | 936,055 | -30.5% | $36.5M |
| JPMORGAN CHASE & CO | ADD | 485,703 | 915,185 | +88.4% | $36.4M |
| RAYMOND JAMES FINANCIAL INC | TRIM | 2,075,403 | 794,660 | -61.7% | $31.0M |
| Jump Financial, LLC | NEW | — | 579,882 | — | $22.6M |
| MILLENNIUM MANAGEMENT LLC | ADD | 250,525 | 498,172 | +98.9% | $19.4M |
| Point72 Asset Management, L.P. | NEW | — | 473,308 | — | $18.5M |
| ExodusPoint Capital Management, LP | DOUBLED | 69,627 | 361,126 | +418.7% | $14.1M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
6 insiders, 10 transactions. Net -$6.1M — $149.9K bought, $6.3M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 1, 2026 | Kelly-Gemmell Dorothy Elizabeth | Director | AWARD | 40,800 | — | — |
| Aug 1, 2026 | Kelly-Gemmell Dorothy Elizabeth | Director | AWARD | 6,333 | — | — |
| Jul 29, 2026 | Mancini Marianna | Chief Operating Officer | SELL | 18,217 | $33.47 | $609.6K |
| Jul 29, 2026 | ZANTE GREG | Chief Financial Officer | SELL | 21,217 | $33.47 | $710.1K |
| Jul 29, 2026 | Lian Brian | President & CEO | SELL | 148,517 | $33.32 | $4.9M |
| Jul 28, 2026 | Mancini Marianna | Chief Operating Officer | AWARD | 31,667 | — | — |
| Jul 28, 2026 | ZANTE GREG | Chief Financial Officer | AWARD | 31,667 | — | — |
| Jul 28, 2026 | Lian Brian | President & CEO | AWARD | 221,667 | — | — |
| Jun 1, 2026 | Chen Hubert C | Chief Medical Officer | AWARD | 190,000 | — | — |
| Mar 10, 2026 | Aubuchon Neil William | Chief Commercial Officer | BUY | 4,475 | $33.50 | $149.9K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for VKTX.
Shares short
22,583,758
Settlement Sep 15, 2026
Change vs prior
+1.8%
Semi-monthly cycle
Days to cover
12.3
At avg daily volume
Of shares outstanding
≈19.4%
Estimate — not % of float
All VKTX filing & press-release reports (3)
- CLUSTER reportAug 8, 2026
- CLUSTER reportJul 30, 2026
- DEFA14A reportApr 1, 2026